GlassScriptPhysician profile
Emily Walden
NPI 1184763849
$5,144.39
in general payments reported to CMS, 2019-2025
29 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,145 · 2022: $878 · 2023: $1,205 · 2024: $549 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $591.30 | 2021-2025 | Caplyta |
| Abbvie INC. | $490.66 | 2021-2025 | |
| Axsome Therapeutics, INC. | $489.65 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $460.93 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Supernus Pharmaceuticals, INC. | $422.97 | 2021-2023 | Qelbree |
| Lundbeck LLC | $341.54 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $264.60 | 2021-2025 | Spravato |
| Corium, LLC | $233.24 | 2022-2025 | Azstarys |
| Eisai INC. | $230.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.64 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $197.44 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $189.83 | 2021-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $184.60 | 2021-2022 | |
| Validus Pharmaceuticals LLC | $136.48 | 2021 | |
| Vanda Pharmaceuticals INC. | $110.68 | 2021-2025 | Fanapt, Hetlioz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $95.97 | 2022-2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $60.45 | 2024-2025 | Xelstrym, Secuado |
| Biogen, INC. | $55.20 | 2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $48.70 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $47.49 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $46.05 | 2021 | |
| Idorsia Pharmaceuticals US INC | $45.32 | 2023 | Quviviq |
| Almatica Pharma LLC | $40.90 | 2023 | Sertraline Hcl, Loreev Xr |
| Bausch Health US, LLC | $39.34 | 2021-2022 | |
| Inspire Medical Systems, INC. | $30.90 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $27.72 | 2024 | Cobenfy |
| Collegium Pharmaceutical, INC. | $17.72 | 2025 | Jornay Pm |
| Aytu Biopharma, INC. | $17.34 | 2021 | |
| Acadia Pharmaceuticals INC | $13.72 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Walden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.